Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)

Launched by YONSEI UNIVERSITY · Jun 14, 2023

Keywords

ClinConnect Summary

The TOLERANT Trial is a study that aims to compare two medications, Rosuvastatin and Atorvastatin, in patients with coronary artery disease who need a specific type of heart stent. This trial is particularly focused on how well these medications help keep "bad" cholesterol (LDL cholesterol) levels low, specifically below 55 mg/dL, which is important for heart health. Researchers want to see which medication works better when combined with Ezetimibe, another drug that helps lower cholesterol.

To participate in this trial, you need to be at least 19 years old and have already had a new generation drug-eluting stent implanted for heart disease. Individuals who have very low cholesterol levels without taking statins, have liver problems, or are pregnant will not be eligible. If you decide to join, you can expect regular check-ups and monitoring to see how well the medications are working for you. This study is currently recruiting participants, and everyone is welcome to apply, regardless of gender.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 19 years of age or older
• • 2. Patients who underwent a new generation of drug elution stent implantation for cardiovascular disease
• Exclusion Criteria:
• • 1. LDL cholesterol levels below 55 mg/dL without statin treatment
• • 2. Serum AST/ALT with an acute liver disease within a month or a normal upper limit that is not continuously explained
• • 3. Allergies or overreactions to statins
• • 4. Estimated Dawn of Less than 1 Year
• • 5. If it is determined that follow-up is not possible for more than one year
• • 6. Pregnancy